The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.